All In Biotech

Drug Trial Radar · NCT06882057

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed Low Risk Childhood B-cell Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Mar 3, 2025

Primary completion

Dec 31, 2029

Study completion Jun 2033

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CCCG-ALL2025 LR-B-ALL plan is designed based on the CCCG-ALL2020 plan. This is a clinical trial using 14 days of blinatumomab (Blina-14) as early intensification after induction therapy and 2nd Blina-14 in consolidation therapy in all newly diagnosed provisional low-risk (LR) pediatric acute lymphoblastic leukemia (ALL) patients, regardless of measurable residual diseases (MRD) status. We will compare the efficacy of chemotherapy combined with Blina-14, comparing to CAT+ intensification or historical regimens. Patients with early remission in depth will receive chemo-light late intensification and maintenance therapy afterwards. Early complete remission in depth and maintenance reduction will be determined by next-generation sequencing (Ig-NGS MRD).

Conditions

  • Acute Lymphoblastic Leukemia ALL
  • Childhood Leukemia, Acute Lymphoblastic
  • B Cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • BlinatumomabDrug

    All LR-B-ALL patients will be treated with 14 days of blinatumomab (Blina-14) as early intensification to replace CAT+ (historically given in LR-B-AL with MRD19\>0.1% in the 2020 protocol). Additionally, second 14 days of blinatumomab will be given after completion of HDMTX consolidation treatment.

  • Reinduction-2 omissionDrug

    Reinduction-2 will be omitted for patients with NGS-MRD46\<10\^-6 who have receive the two courses of Blina-14.

  • Chemo-light Maintenance 2Drug

    Patients with FCM-MRD19\<0.01% and IgH rearrangement NGS MRD 46\<10\^-6 will receive chemo-light maintenance-2 with 4 cyles of 8-week course of MTX + 6MP (totally 32 weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare 3-year event-free survival (EFS) between patients who receive Blina-14 intensification with this historical controls from CCCG-ALL2015 and CCCG-ALL2000Time frame: The expected study duration is approximately 5 years.

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Anhui Medical University Second Affiliated Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Anhui Provincial Children's Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Chongqing Medical University Affiliated Children's Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Wuhan Children's Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Children's Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Third Xiangya Hospital of the Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Nanjing Children's Hospital Affiliated to Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • Jiangxi Provincial Children's Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Not yet recruiting

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanghai Children's Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanghai Children's Medical Cener, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Xi'an Northwest Women and Children Hospital

    Xi’an, Shanxi, China · Not yet recruiting

  • Shenzhen Children's Hospita

    Shenzhen, Shenzhen, China · Not yet recruiting

  • West China Second University Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC

    Tianjin, Tianjin Municipality, China · Recruiting

  • Hong Kong Children's Hospital

    Hong Kong, Hong Kong, Hong Kong · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.